EO2002 for Corneal Edema

(EMERALD Trial)

This trial tests a new treatment called EO2002 for individuals with corneal edema, a condition where the cornea swells due to issues with corneal cells. The study compares different doses of EO2002, which uses special cells, to a placebo to evaluate its effectiveness and safety. It suits those experiencing vision loss from corneal edema related to conditions like Fuchs corneal dystrophy or pseudophakic bullous keratopathy and who are considering corneal surgery. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant advancements in corneal edema treatment.

Research has shown that EO2002, a treatment for corneal swelling, has been tested for safety and tolerability. In earlier studies, patients received a single injection of EO2002. This treatment uses magnetic human corneal endothelial cells (mHCECs) to enhance eye health.

Results from these studies suggest that EO2002 is generally well-tolerated. The use of magnets to deliver the cells does not appear to harm the cells or patients. Unwanted side effects were not commonly reported, indicating that EO2002 might be a safe option for those with corneal swelling.

Unlike the standard treatments for corneal edema, which often involve eye drops or surgery, EO2002 is an innovative approach using magnetic human corneal endothelial cells. This treatment involves an intracameral injection, directly introducing 150K or 500K cells into the eye, aiming to repair and regenerate the damaged corneal tissue. Researchers are excited because this method could potentially restore vision by directly addressing the underlying cell loss, offering a more direct and regenerative solution compared to current options.

Research has shown that EO2002 may help treat corneal edema, a condition involving swelling in the eye due to issues with the eye's inner layer. In this trial, participants will receive different doses of EO2002; some will receive an intracameral injection of 150K magnetic human corneal endothelial cells, while others will receive 500K cells. Earlier studies demonstrated that patients treated with special magnetic cells, like those in EO2002, experienced significant vision improvements. Specifically, nine out of 21 patients could see three lines better on an eye chart, indicating clearer vision. Importantly, no safety issues emerged after 12 months. The magnetic cells help direct the treatment to the correct part of the eye, potentially enhancing its effectiveness. These findings suggest that EO2002 could improve vision for people with corneal edema.²⁴⁶⁷⁸